A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS] - CTQJ230A12203

ovartis Pharma AG0 个研究点目标入组 502 人开始时间: 2024年2月2日最近更新: 2024年8月21日

适应症

试验速览

暂无简介。

•Male and female =50 to <80 years of age, Lipoprotein(a) =175 nmol/L at Screening-Part I, measured at the central laboratory, Mild or moderate calcific aortic valve stenosis as defined by a peak aortic jet velocity =2.5 m/s and =3.5 m/s at Screening-Part II, as assessed by the core laboratory, At the randomization visit, participant must be optimally treated for existing CV risk factors (e.g. LDL-C, Diabetes Mellitus and hypertension according to local practice/guidelines)

•Severe calcific aortic valve stenosis defined by mean gradient >40 mmHg or aortic valve area <1 cm2 at Screening-Part II, as assessed by the core laboratory, History of hemorrhagic stroke or other major bleeding, Platelet count <140,000 per mm3, Active liver disease or hepatic dysfunction, Significant kidney disease, Pregnant or nursing women, Planned aortic valve intervention, Unicuspid valve or other congenital cardiac anomaly (bicuspid aortic valve morphology is not excluded), at Screening-Part II, as assessed by the core laboratory, Severe mitral valve stenosis (valve area <1.5 cm2), severe mitral valve regurgitation, or severe aortic valve regurgitation at Screening-Part II, as assessed by the core laboratory, Inability to undergo or to acquire an optimal echocardiogram or computed tomography, or contraindication to computed tomography contrast media, Left ventricular ejection fraction <55% at Screening-Part II, as assessed by the core laboratory, Heart failure New York Heart Association class III - IV at Screening-Part II or at Randomization visit (Day 1), Uncontrolled hypertension, History of malignancy of any organ system

发起方